Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia
CONCLUSION: The starting dosage of dasatinib may need to be reduced (eg, 80 mg once daily or lower) for Asian patients with CP-CML, especially with lighter BW, to alleviate the risk of DLT occurrence without compromising the achievement of MR.PMID:33632667 | DOI:10.1016/j.clml.2021.01.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Hyejin Shin Jung-Eun Ha Dae Young Zang Sung-Hyun Kim Young Rok Do Won Sik Lee Dong-Wook Kim Jangik I Lee Source Type: research

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CONCLUSION: The primary endpoint was met, with durvalumab plus tremelimumab/danvatirsen generally well tolerated in patients with relapsed/refractory DLBCL; however, antitumor activity was limited.PMID:33632668 | DOI:10.1016/j.clml.2020.12.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Vincent Ribrag Seung Tae Lee David Rizzieri Martin J S Dyer Luis Fayad Razelle Kurzrock Leslie Andritsos Reda Bouabdallah Amjad Hayat Larry Bacon Yu Jiang Kowser Miah Bruno Delafont Oday Hamid Stephanie Anyanwu Pablo Martinez Brian Hess Source Type: research

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia
CONCLUSION: The starting dosage of dasatinib may need to be reduced (eg, 80 mg once daily or lower) for Asian patients with CP-CML, especially with lighter BW, to alleviate the risk of DLT occurrence without compromising the achievement of MR.PMID:33632667 | DOI:10.1016/j.clml.2021.01.020 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Hyejin Shin Jung-Eun Ha Dae Young Zang Sung-Hyun Kim Young Rok Do Won Sik Lee Dong-Wook Kim Jangik I Lee Source Type: research

A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CONCLUSION: The primary endpoint was met, with durvalumab plus tremelimumab/danvatirsen generally well tolerated in patients with relapsed/refractory DLBCL; however, antitumor activity was limited.PMID:33632668 | DOI:10.1016/j.clml.2020.12.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Vincent Ribrag Seung Tae Lee David Rizzieri Martin J S Dyer Luis Fayad Razelle Kurzrock Leslie Andritsos Reda Bouabdallah Amjad Hayat Larry Bacon Yu Jiang Kowser Miah Bruno Delafont Oday Hamid Stephanie Anyanwu Pablo Martinez Brian Hess Source Type: research

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis
Clin Lymphoma Myeloma Leuk. 2021 Feb 2:S2152-2650(21)00040-9. doi: 10.1016/j.clml.2021.01.021. Online ahead of print.NO ABSTRACTPMID:33622658 | DOI:10.1016/j.clml.2021.01.021 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 24, 2021 Category: Cancer & Oncology Authors: Jose Acevedo Gheorghe Doros Raphael Szalat Vaishali Sanchorawala Source Type: research

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis
Clin Lymphoma Myeloma Leuk. 2021 Feb 2:S2152-2650(21)00040-9. doi: 10.1016/j.clml.2021.01.021. Online ahead of print.NO ABSTRACTPMID:33622658 | DOI:10.1016/j.clml.2021.01.021 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 24, 2021 Category: Cancer & Oncology Authors: Jose Acevedo Gheorghe Doros Raphael Szalat Vaishali Sanchorawala Source Type: research

Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Jan 19:S2152-2650(21)00019-7. doi: 10.1016/j.clml.2021.01.011. Online ahead of print.ABSTRACTBACKGROUND: Relapsed/refractory acute myeloid leukemia (AML) confers a poor prognosis, and there is no single standard of care first-line salvage regimen. FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor) is a common salvage regimen with a favorable toxicity and efficacy profile in poor-risk AML.MATERIALS AND METHODS: We conducted a single-center, retrospective analysis of first relapse/primary refractory patients with AML that received salvage chemotherapy from January 2009 ...
Source: Clinical Lymphoma and Myeloma - February 22, 2021 Category: Cancer & Oncology Authors: Justin H Reid Bernard L Marini Lydia L Benitez Kristen Pettit Dale L Bixby Patrick Burke Anthony J Perissinotti Source Type: research

Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2021 Jan 19:S2152-2650(21)00019-7. doi: 10.1016/j.clml.2021.01.011. Online ahead of print.ABSTRACTBACKGROUND: Relapsed/refractory acute myeloid leukemia (AML) confers a poor prognosis, and there is no single standard of care first-line salvage regimen. FLAG (fludarabine, cytarabine, and granulocyte colony-stimulating factor) is a common salvage regimen with a favorable toxicity and efficacy profile in poor-risk AML.MATERIALS AND METHODS: We conducted a single-center, retrospective analysis of first relapse/primary refractory patients with AML that received salvage chemotherapy from January 2009 ...
Source: Clinical Lymphoma and Myeloma - February 22, 2021 Category: Cancer & Oncology Authors: Justin H Reid Bernard L Marini Lydia L Benitez Kristen Pettit Dale L Bixby Patrick Burke Anthony J Perissinotti Source Type: research

Advances in Frontline Management of Peripheral T-cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2021 Jan 22:S2152-2650(21)00020-3. doi: 10.1016/j.clml.2021.01.012. Online ahead of print.ABSTRACTPeripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. For many decades, the standard-of-care has been CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based therapy, but it is well-recognized that survival outcomes are unsatisfactory, especially when compared with B-cell lymphomas. Major recent advances in cancer diagnosis and management have the potential to significantly improve PTCL outcomes. These inclu...
Source: Clinical Lymphoma and Myeloma - February 21, 2021 Category: Cancer & Oncology Authors: Chathuri Abeyakoon Carrie van der Weyden Sean Harrop Amit Khot Michael Dickinson Costas K Yannakou H Miles Prince Source Type: research

Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
CONCLUSION: This study emphasizes the difficulties in recruiting patients for cell therapy trials, though NKAE cell infusion is safe and feasible. However, we cannot draw any conclusions regarding efficacy because of the small number of included patients and insufficient biological markers.PMID:33610500 | DOI:10.1016/j.clml.2021.01.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 21, 2021 Category: Cancer & Oncology Authors: Lara Maria G ómez García Adela Escudero Carmen Mestre Jose L Fuster Soler Antonia Pascual Mart ínez Jose M Vagace Valero Mar ía Vela Beatriz Ruz Alfonso Navarro Lucia Fern ández Adri án Fernández Alejandra Leivas Joaquin Mart ínez-López Cristina Source Type: research

Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2021 Jan 14:S2152-2650(21)00010-0. doi: 10.1016/j.clml.2021.01.009. Online ahead of print.NO ABSTRACTPMID:33608216 | DOI:10.1016/j.clml.2021.01.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 20, 2021 Category: Cancer & Oncology Authors: Eyal Lebel Christine Chen Harminder Paul Suzanne Trudel Rodger Tiedemann Source Type: research

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Nat Rev Clin Oncol. 2021 Feb 19. doi: 10.1038/s41571-021-00474-4. Online ahead of print.ABSTRACTCancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell...
Source: Clinical Lymphoma and Myeloma - February 20, 2021 Category: Cancer & Oncology Authors: Dristhi Ragoonanan Sajad J Khazal Hisham Abdel-Azim David McCall Branko Cuglievan Francesco Paolo Tambaro Ali Haider Ahmad Courtney M Rowan Cristina Gutierrez Keri Schadler Shulin Li Matteo Di Nardo Linda Chi Alison M Gulbis Basirat Shoberu Maria E Mirele Source Type: research

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
B, Duncun CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Abstract Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint i...
Source: Clinical Lymphoma and Myeloma - February 19, 2021 Category: Cancer & Oncology Authors: Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill Tags: Nat Rev Clin Oncol Source Type: research

Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?
CONCLUSION: Overall survival is improved when receiving autologous hematopoietic stem-cell transplantation as up-front therapy at first relapse in transplant-eligible FL whose disease relapses within 24 months of first-line therapy. Data from our single center look promising, but the data need to be replicated with a larger sample size. PMID: 33558203 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 5, 2021 Category: Cancer & Oncology Authors: Yahya A, Radhwi O, Sobh M, Huebsch L, MacDonald D Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Regression of Marginal Zone Lymphoma After Praziquantel Therapy in a Patient With Remote Schistosoma haematobium Infection.
PMID: 33509726 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 25, 2021 Category: Cancer & Oncology Authors: Thu MB, Htun NN, Soe KHH, Steinberg A, McKinley G, Varma M, Yoe J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-M ünster Chemotherapy in Adult Acute Lymphoblastic Leukemia.
Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 Jan 12;: Authors: Aladag E, Aktimur SH, Aydın Ö, Demiroglu H, Buyukasik Y, Aksu S, Ozcebe OI, Haznedaroglu IC, Sayinalp N, Turgut M, Goker H Abstract INTRODUCTION: Acute lymphoblastic leukemia (ALL) is a malign disease with poor prognosis in adults. After remission is achieved by induction therapy, administration of allogeneic hematopoietic stem-cell transplantation (AHSC...
Source: Clinical Lymphoma and Myeloma - January 12, 2021 Category: Cancer & Oncology Authors: Aladag E, Aktimur SH, Aydın Ö, Demiroglu H, Buyukasik Y, Aksu S, Ozcebe OI, Haznedaroglu IC, Sayinalp N, Turgut M, Goker H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies.
PMID: 33434058 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 12, 2021 Category: Cancer & Oncology Authors: Reagan PM, Neelapu SS Tags: J Clin Oncol Source Type: research

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
Abstract INTRODUCTION: Polatuzumab vedotin is approved therapy in the United States for relapsed/refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab (Pola+BR). However, the safety and efficacy of Pola+BR outside of a clinical trial setting is unknown. PATIENTS AND METHODS: We analyzed use of pola-based therapy at 5 centers in the United States, including dose, response rates, progression-free survival (PFS), survival, and toxicity. RESULTS: Sixty-nine patients with aggressive B-cell lymphoma, including 66 with diffuse large B-cell lymphoma/high-grade B-cell lymphoma an...
Source: Clinical Lymphoma and Myeloma - December 18, 2020 Category: Cancer & Oncology Authors: Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Understanding Geriatrics-based Assessment in Hematologic Malignancies and Bone Marrow Transplant Patients.
PMID: 33419716 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 17, 2020 Category: Cancer & Oncology Authors: Ruiz M, Cristian A, Chaves P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Weisel K Abstract PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE)...
Source: Clinical Lymphoma and Myeloma - December 16, 2020 Category: Cancer & Oncology Authors: Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J Tags: J Clin Oncol Source Type: research

Systemic Amyloidosis due to Low-Grade Lymphoma.
Abstract Lymphoma-related amyloidosis is a rare entity. Systemic AL amyloidosis is generally caused by an underlying plasma cell clone in the bone marrow with an intact monoclonal immunoglobulin G (IgG) or IgA protein. The rarity of the lymphoma-related amyloidosis makes the generation of data in randomized trials and the determination of the optimal treatment almost impossible. Therefore, treatment recommendations discussed here are based on either retrospective or small prospective trials of single centers. PMID: 33099421 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 28, 2020 Category: Cancer & Oncology Authors: Wechalekar AD, Chakraborty R, Lentzsch S Tags: Hematol Oncol Clin North Am Source Type: research

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.
PMID: 33074750 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 19, 2020 Category: Cancer & Oncology Authors: Jain P, Dreyling M, Seymour JF, Wang M Tags: J Clin Oncol Source Type: research

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
CONCLUSIONS: Combined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation. PMID: 33055173 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 14, 2020 Category: Cancer & Oncology Authors: Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA Tags: Clin Cancer Res Source Type: research

Physical Activity in People with Multiple Myeloma: Associated Factors and Exercise Program Preferences.
This study explored PA among people with MM, including differences by treatment stage, symptoms and demographics, and programming preferences. Overall, 126 people with MM (77% response rate) completed the survey. Pre-diagnosis, 25.4% were sufficiently active, with 12.0% remaining active after treatment. Respondents who were physically active pre-diagnosis were 46.7 times (95% confidence intervals CI: 2.03, 1072.1) more likely to meet PA guidelines following an MM diagnosis compared to people not meeting guidelines pre-diagnosis. Experiencing MM symptoms and receiving PA advice from healthcare professionals were not associa...
Source: Clinical Lymphoma and Myeloma - October 13, 2020 Category: Cancer & Oncology Authors: Nicol JL, Woodrow C, Burton NW, Mollee P, Nicol AJ, Hill MM, Skinner TL Tags: J Clin Med Source Type: research

Blastoid Mantle Cell Lymphoma.
This article presents a comprehensive review on blastoid MCL in 2020. PMID: 32861288 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 1, 2020 Category: Cancer & Oncology Authors: Jain P, Wang M Tags: Hematol Oncol Clin North Am Source Type: research

Message from the Chairmen.
PMID: 32862847 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Lonial S, Kantarjian H, Freireich EJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Update on CML-Like Disorders.
Abstract Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed 'BCR-ABL1 negative CML' constituting about 5% of CML cases. Apart from very rare CML cases with cytogenetically cryptic, atypical variant BCR-ABL1 fusions that had been inadvertently missed during the diagnostic work up, most of these cases would now be classified as a subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN), such as atypical CML (aCML), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemi...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Cross NCP Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Next Questions - Classical Hodgkin Lymphoma (cHL).
PMID: 32862849 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Straus DJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Asparaginase Toxicity in AYAs with ALL.
PMID: 32862850 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Schmiegelow K, Rank CU Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Young Woman with Thrombocytosis.
Abstract The diagnostic approach to thrombocytosis involves consideration of reactive, hereditary, and neoplastic causes. Once reactive causes of thrombocytosis, such as iron deficiency, infections, solid tumors, and other obvious causes such as post-splenectomy thrombocytosis, have been ruled out, the focus shifts to myeloid malignancies, such as chronic myeloid leukemia (CML), the classic Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), primary myelofibrosis (PMF), polycythemia vera (PV), myelodysplastic syndrome (MDS) with isolated deletion 5q and the r...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Bose P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Case Presentation: A Young Man with Polycythemia Vera and Fatigue.
PMID: 32862852 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Hobbs G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis.
Abstract In patients with myelofibrosis (MF), allogeneic stem cell transplantation (SCT) is a curative treatment, but does entail risk of treatment-related mortality (TRM). Furthermore, a minority of patients cured of myelofibrosis are at risk of chronic graft-versus-host disease (GvHD) that may impair their quality of life. It is also pertinent to note that transplant early in the disease course results in better transplant outcome than transplant late in the disease course.1 Thus, the survival benefit of SCT needs to be weighed against early transplant related mortality (TRM) and morbidity, as well as impaired q...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Joseph J, Popat U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Pitfalls in Assessing Response to Treatment in MDS.
PMID: 32862854 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Platzbecker U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

BTK Inhibitors and Chemoimmunotherapy for CLL.
PMID: 32862855 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Thompson P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Venetoclax in AML: Where We Are and Where We Are Headed.
Abstract The developmental path for venetoclax in acute myeloid leukemia (AML) has been rapid and stands in stark contrast to the incremental progress that has characterized the field in previous decades. For perspective, on December 31, 2013, the first AML patient was enrolled into a study using venetoclax; 59 months later, on November 21, 2018, venetoclax received accelerated approval by the FDA for use in AML. In June 2020, Dr. DiNardo presented the results of the required confirmatory study at the European Hematology Association meeting, showing that venetoclax with azacitidine resulted in a superior response ...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Pollyea DA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hereditary Hematologic Malignancies.
PMID: 32862857 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: DiNardo C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

IDH Inhibition.
PMID: 32862858 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: de Botton S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies.
PMID: 32862859 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Jabbour E, Kantarjian H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

How I Approach the Patient Who Has MRD or Relapse After Transplant.
PMID: 32862860 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Muffly L Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Early (Limited)-Stage DLBCL.
PMID: 32862861 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Kumar A, Persky DO Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Burkitt Lymphoma - Subtypes, Pathogenesis, and Treatment Strategies.
Abstract Burkitt's lymphoma (BL) is a rare and highly aggressive Non-Hodgkin lymphoma (NHL) with a germinal center phenotype, a nearly universal myc oncogene translocation to an enhancer element and a proliferation index greater than 95%.1 Bcl-2 is not expressed as opposed to double-hit or triple-hit lymphoma. Genetic mutations and aberrancy involving the phosphatidylcholine 3-kinase and cyclin-dependent kinase pathways are also involved.2-5 Rarely patients present with stage I disease and others are considered as high risk if greater than stage I or with elevated LDH or masses greater than 10 cm. PMID: 32862...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Noy A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Waldenstr öm Macroglobulinemia - 2020 Update on Management and Future Directions.
Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions. Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S39-S41 Authors: Thomas SK PMID: 32862863 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Thomas SK Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bone Diseases and Supportive Care.
PMID: 32862864 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Hillengass J, Merz M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future.
PMID: 32862865 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Luskin MR, DeAngelo DJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Who Should Receive an Allogeneic Transplant in First Complete Remission?
era J Abstract The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Ribera JM, Genescà E, Ribera J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

FLT3 Inhibition in Acute Myeloid Leukemia.
Abstract Mutations in the FLT3 receptor tyrosine kinase are the most frequently found mutations in acute myeloid leukemia (AML). Patients with FLT3 internal tandem duplication (ITD) mutations have poor prognoses. The approved FLT3 tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve survival in AML with FLT3 mutations. Multiple other FLT3 inhibitors are in clinical development. Patients frequently relapse after response to FLT3 inhibitors and the optimal use of FLT3 inhibitors in the upfront, relapse, and maintenance settings remain to be established. We will discuss the biology of FLT3, approved...
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Smith CC Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care.
PMID: 32862868 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Short NJ, Jabbour E Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Is Less More? Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL.
PMID: 32862869 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Chiaretti S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Immunotherapy for T-Cell ALL and T-Cell NHL.
PMID: 32862870 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: DiPersio JF, Staser K, Cooper M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

New Approaches for Anemia in MDS.
PMID: 32862871 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 31, 2020 Category: Cancer & Oncology Authors: Platzbecker U Tags: Clin Lymphoma Myeloma Leuk Source Type: research